Rare autosomal recessive disorder of INTERMEDIATE FILAMENT PROTEINS. The disease is caused by mutations in the gene that codes gigaxonin protein. The mutations result in disorganization of axonal NEUROFILAMENT PROTEINS, formation of the characteristic giant axons, and progressive neuropathy. The clinical features of the disease include early-onset progressive peripheral motor and sensory neuropathies often associated with central nervous system involvement (INTELLECTUAL DISABILITY, seizures, DYSMETRIA, and CONGENITAL NYSTAGMUS).
Inherited disorders characterized by progressive atrophy and dysfunction of anatomically or physiologically related neurologic systems.
A branch of the tibial nerve which supplies sensory innervation to parts of the lower leg and foot.
Diseases of the peripheral nerves external to the brain and spinal cord, which includes diseases of the nerve roots, ganglia, plexi, autonomic nerves, sensory nerves, and motor nerves.
Nerve fibers that are capable of rapidly conducting impulses away from the neuron cell body.
An acute inflammatory autoimmune neuritis caused by T cell- mediated cellular immune response directed towards peripheral myelin. Demyelination occurs in peripheral nerves and nerve roots. The process is often preceded by a viral or bacterial infection, surgery, immunization, lymphoma, or exposure to toxins. Common clinical manifestations include progressive weakness, loss of sensation, and loss of deep tendon reflexes. Weakness of respiratory muscles and autonomic dysfunction may occur. (From Adams et al., Principles of Neurology, 6th ed, pp1312-1314)
Diseases of multiple peripheral nerves simultaneously. Polyneuropathies usually are characterized by symmetrical, bilateral distal motor and sensory impairment with a graded increase in severity distally. The pathological processes affecting peripheral nerves include degeneration of the axon, myelin or both. The various forms of polyneuropathy are categorized by the type of nerve affected (e.g., sensory, motor, or autonomic), by the distribution of nerve injury (e.g., distal vs. proximal), by nerve component primarily affected (e.g., demyelinating vs. axonal), by etiology, or by pattern of inheritance.
A hereditary motor and sensory neuropathy transmitted most often as an autosomal dominant trait and characterized by progressive distal wasting and loss of reflexes in the muscles of the legs (and occasionally involving the arms). Onset is usually in the second to fourth decade of life. This condition has been divided into two subtypes, hereditary motor and sensory neuropathy (HMSN) types I and II. HMSN I is associated with abnormal nerve conduction velocities and nerve hypertrophy, features not seen in HMSN II. (Adams et al., Principles of Neurology, 6th ed, p1343)
A group of slowly progressive inherited disorders affecting motor and sensory peripheral nerves. Subtypes include HMSNs I-VII. HMSN I and II both refer to CHARCOT-MARIE-TOOTH DISEASE. HMSN III refers to hypertrophic neuropathy of infancy. HMSN IV refers to REFSUM DISEASE. HMSN V refers to a condition marked by a hereditary motor and sensory neuropathy associated with spastic paraplegia (see SPASTIC PARAPLEGIA, HEREDITARY). HMSN VI refers to HMSN associated with an inherited optic atrophy (OPTIC ATROPHIES, HEREDITARY), and HMSN VII refers to HMSN associated with retinitis pigmentosa. (From Adams et al., Principles of Neurology, 6th ed, p1343)
Peripheral, autonomic, and cranial nerve disorders that are associated with DIABETES MELLITUS. These conditions usually result from diabetic microvascular injury involving small blood vessels that supply nerves (VASA NERVORUM). Relatively common conditions which may be associated with diabetic neuropathy include third nerve palsy (see OCULOMOTOR NERVE DISEASES); MONONEUROPATHY; mononeuropathy multiplex; diabetic amyotrophy; a painful POLYNEUROPATHY; autonomic neuropathy; and thoracoabdominal neuropathy. (From Adams et al., Principles of Neurology, 6th ed, p1325)
The propagation of the NERVE IMPULSE along the nerve away from the site of an excitation stimulus.
Diagnosis of disease states by recording the spontaneous electrical activity of tissues or organs or by the response to stimulation of electrically excitable tissue.
Diseases characterized by injury or dysfunction involving multiple peripheral nerves and nerve roots. The process may primarily affect myelin or nerve axons. Two of the more common demyelinating forms are acute inflammatory polyradiculopathy (GUILLAIN-BARRE SYNDROME) and POLYRADICULONEUROPATHY, CHRONIC INFLAMMATORY DEMYELINATING. Polyradiculoneuritis refers to inflammation of multiple peripheral nerves and spinal nerve roots.
Diseases characterized by loss or dysfunction of myelin in the central or peripheral nervous system.
A subclass of ACIDIC GLYCOSPHINGOLIPIDS. They contain one or more sialic acid (N-ACETYLNEURAMINIC ACID) residues. Using the Svennerholm system of abbrevations, gangliosides are designated G for ganglioside, plus subscript M, D, or T for mono-, di-, or trisialo, respectively, the subscript letter being followed by a subscript arabic numeral to indicated sequence of migration in thin-layer chromatograms. (From Oxford Dictionary of Biochemistry and Molecular Biology, 1997)
The record of descent or ancestry, particularly of a particular condition or trait, indicating individual family members, their relationships, and their status with respect to the trait or condition.
A class of enzymes that catalyze the hydrolysis of one of the two ester bonds in a phosphodiester compound. EC 3.1.4.
Loss of functional activity and trophic degeneration of nerve axons and their terminal arborizations following the destruction of their cells of origin or interruption of their continuity with these cells. The pathology is characteristic of neurodegenerative diseases. Often the process of nerve degeneration is studied in research on neuroanatomical localization and correlation of the neurophysiology of neural pathways.
Recording of the changes in electric potential of muscle by means of surface or needle electrodes.

Proximal giant neurofilamentous axonopathy in mice genetically engineered to resist calpain and caspase cleavage of alpha-II spectrin. (1/3)

 (+info)

Application of autologous bone marrow stem cells in giant axonal neuropathy. (2/3)

 (+info)

Giant axonal neuropathy-associated gigaxonin mutations impair intermediate filament protein degradation. (3/3)

 (+info)

Giant Axonal Neuropathy (GAN) is a rare inherited genetic disorder that affects the peripheral nerves, and in some cases, the central nervous system. The condition is characterized by the abnormal accumulation of a protein called neurofilament within the axons of nerve cells, leading to their progressive damage and degeneration.

The name "giant axonal" refers to the swelling of the axons due to the accumulation of neurofilaments, which are normally involved in maintaining the structure and function of nerve cells. In GAN, these neurofilaments become tangled and form large clumps that disrupt the normal functioning of the axons.

The symptoms of GAN typically begin in childhood or early adolescence and can vary in severity. They often include muscle weakness, decreased reflexes, loss of sensation in the limbs, and difficulty with coordination and balance. Over time, these symptoms can progress to involve more severe muscle wasting, curvature of the spine (scoliosis), and respiratory complications.

GAN is caused by mutations in the GAN gene, which provides instructions for making a protein called gigaxonin. This protein plays a crucial role in regulating the breakdown and recycling of neurofilaments within nerve cells. When the GAN gene is mutated, gigaxonin function is impaired, leading to the accumulation of neurofilaments and the development of GAN. Currently, there is no cure for GAN, and treatment is focused on managing symptoms and maintaining quality of life.

Heredodegenerative disorders of the nervous system are a group of inherited conditions that involve progressive degeneration of the nervous system over time. These disorders are caused by genetic mutations that affect the development and function of nerve cells in the brain and spinal cord. The symptoms and severity of these disorders can vary widely, depending on the specific condition and the location and extent of nerve cell damage.

Examples of heredodegenerative disorders of the nervous system include:

1. Huntington's disease: a genetic disorder that causes the progressive breakdown of nerve cells in the brain, leading to uncontrolled movements, emotional problems, and cognitive decline.
2. Friedreich's ataxia: an inherited disorder that affects the nerves and muscle coordination, causing symptoms such as difficulty walking, poor balance, and speech problems.
3. Spinal muscular atrophy: a genetic disorder that affects the motor neurons in the spinal cord, leading to muscle weakness and wasting.
4. Hereditary sensory and autonomic neuropathies: a group of inherited disorders that affect the nerves that control sensation and automatic functions such as heart rate and digestion.
5. Leukodystrophies: a group of genetic disorders that affect the white matter of the brain, leading to symptoms such as motor and cognitive decline, seizures, and vision loss.

Treatment for heredodegenerative disorders of the nervous system typically focuses on managing symptoms and improving quality of life. There is no cure for most of these conditions, but research is ongoing to develop new treatments and therapies that may help slow or stop the progression of nerve cell damage.

The sural nerve is a purely sensory peripheral nerve in the lower leg and foot. It provides sensation to the outer ( lateral) aspect of the little toe and the adjacent side of the fourth toe, as well as a small portion of the skin on the back of the leg between the ankle and knee joints.

The sural nerve is formed by the union of branches from the tibial and common fibular nerves (branches of the sciatic nerve) in the lower leg. It runs down the calf, behind the lateral malleolus (the bony prominence on the outside of the ankle), and into the foot.

The sural nerve is often used as a donor nerve during nerve grafting procedures due to its consistent anatomy and relatively low risk for morbidity at the donor site.

Peripheral Nervous System (PNS) diseases, also known as Peripheral Neuropathies, refer to conditions that affect the functioning of the peripheral nervous system, which includes all the nerves outside the brain and spinal cord. These nerves transmit signals between the central nervous system (CNS) and the rest of the body, controlling sensations, movements, and automatic functions such as heart rate and digestion.

PNS diseases can be caused by various factors, including genetics, infections, toxins, metabolic disorders, trauma, or autoimmune conditions. The symptoms of PNS diseases depend on the type and extent of nerve damage but often include:

1. Numbness, tingling, or pain in the hands and feet
2. Muscle weakness or cramps
3. Loss of reflexes
4. Decreased sensation to touch, temperature, or vibration
5. Coordination problems and difficulty with balance
6. Sexual dysfunction
7. Digestive issues, such as constipation or diarrhea
8. Dizziness or fainting due to changes in blood pressure

Examples of PNS diseases include Guillain-Barre syndrome, Charcot-Marie-Tooth disease, diabetic neuropathy, and peripheral nerve injuries. Treatment for these conditions varies depending on the underlying cause but may involve medications, physical therapy, lifestyle changes, or surgery.

An axon is a long, slender extension of a neuron (a type of nerve cell) that conducts electrical impulses (nerve impulses) away from the cell body to target cells, such as other neurons or muscle cells. Axons can vary in length from a few micrometers to over a meter long and are typically surrounded by a myelin sheath, which helps to insulate and protect the axon and allows for faster transmission of nerve impulses.

Axons play a critical role in the functioning of the nervous system, as they provide the means by which neurons communicate with one another and with other cells in the body. Damage to axons can result in serious neurological problems, such as those seen in spinal cord injuries or neurodegenerative diseases like multiple sclerosis.

Guillain-Barré syndrome (GBS) is a rare autoimmune disorder in which the body's immune system mistakenly attacks the peripheral nervous system, leading to muscle weakness, tingling sensations, and sometimes paralysis. The peripheral nervous system includes the nerves that control our movements and transmit signals from our skin, muscles, and joints to our brain.

The onset of GBS usually occurs after a viral or bacterial infection, such as respiratory or gastrointestinal infections, or following surgery, vaccinations, or other immune system triggers. The exact cause of the immune response that leads to GBS is not fully understood.

GBS typically progresses rapidly over days or weeks, with symptoms reaching their peak within 2-4 weeks after onset. Most people with GBS experience muscle weakness that starts in the lower limbs and spreads upward to the upper body, arms, and face. In severe cases, the diaphragm and chest muscles may become weakened, leading to difficulty breathing and requiring mechanical ventilation.

The diagnosis of GBS is based on clinical symptoms, nerve conduction studies, and sometimes cerebrospinal fluid analysis. Treatment typically involves supportive care, such as pain management, physical therapy, and respiratory support if necessary. In addition, plasma exchange (plasmapheresis) or intravenous immunoglobulin (IVIG) may be used to reduce the severity of symptoms and speed up recovery.

While most people with GBS recover completely or with minimal residual symptoms, some may experience long-term disability or require ongoing medical care. The prognosis for GBS varies depending on the severity of the illness and the individual's age and overall health.

Polyneuropathy is a medical condition that refers to the damage or dysfunction of peripheral nerves (nerves outside the brain and spinal cord) in multiple areas of the body. These nerves are responsible for transmitting sensory, motor, and autonomic signals between the central nervous system and the rest of the body.

In polyneuropathies, this communication is disrupted, leading to various symptoms depending on the type and extent of nerve damage. Commonly reported symptoms include:

1. Numbness or tingling in the hands and feet
2. Muscle weakness and cramps
3. Loss of reflexes
4. Burning or stabbing pain
5. Balance and coordination issues
6. Increased sensitivity to touch
7. Autonomic dysfunction, such as bowel, bladder, or digestive problems, and changes in blood pressure

Polyneuropathies can be caused by various factors, including diabetes, alcohol abuse, nutritional deficiencies, autoimmune disorders, infections, toxins, inherited genetic conditions, or idiopathic (unknown) causes. The treatment for polyneuropathy depends on the underlying cause and may involve managing underlying medical conditions, physical therapy, pain management, and lifestyle modifications.

Charcot-Marie-Tooth disease (CMT) is a group of inherited disorders that cause nerve damage, primarily affecting the peripheral nerves. These are the nerves that transmit signals between the brain and spinal cord to the rest of the body. CMT affects both motor and sensory nerves, leading to muscle weakness and atrophy, as well as numbness or tingling in the hands and feet.

The disease is named after the three physicians who first described it: Jean-Martin Charcot, Pierre Marie, and Howard Henry Tooth. CMT is characterized by its progressive nature, meaning symptoms typically worsen over time, although the rate of progression can vary significantly among individuals.

There are several types of CMT, classified based on their genetic causes and patterns of inheritance. The two most common forms are CMT1 and CMT2:

1. CMT1: This form is caused by mutations in the genes responsible for the myelin sheath, which insulates peripheral nerves and allows for efficient signal transmission. As a result, demyelination occurs, slowing down nerve impulses and causing muscle weakness, particularly in the lower limbs. Symptoms usually begin in childhood or adolescence and include foot drop, high arches, and hammertoes.
2. CMT2: This form is caused by mutations in the genes responsible for the axons, the nerve fibers that transmit signals within peripheral nerves. As a result, axonal degeneration occurs, leading to muscle weakness and atrophy. Symptoms usually begin in early adulthood and progress more slowly than CMT1. They primarily affect the lower limbs but can also involve the hands and arms.

Diagnosis of CMT typically involves a combination of clinical evaluation, family history, nerve conduction studies, and genetic testing. While there is no cure for CMT, treatment focuses on managing symptoms and maintaining mobility and function through physical therapy, bracing, orthopedic surgery, and pain management.

Hereditary Sensory and Motor Neuropathy (HSMN) is a group of inherited disorders that affect the peripheral nerves, which are the nerves outside the brain and spinal cord. These nerves transmit information between the brain and muscles, as well as sensations such as touch, pain, heat, and cold.

HSMN is characterized by progressive degeneration of these peripheral nerves, leading to muscle weakness, numbness, and tingling sensations, particularly in the hands and feet. The condition can also affect the autonomic nervous system, which controls involuntary functions such as heart rate, blood pressure, and digestion.

HSMN is caused by genetic mutations that are inherited from one or both parents. There are several types of HSMN, each with its own specific symptoms, severity, and pattern of inheritance. The most common form is Charcot-Marie-Tooth disease (CMT), which affects both motor and sensory nerves.

Treatment for HSMN typically focuses on managing the symptoms and preventing complications. This may include physical therapy, bracing or orthopedic surgery to support weakened muscles, pain management, and lifestyle modifications such as avoiding activities that aggravate symptoms. There is currently no cure for HSMN, but ongoing research is aimed at developing new treatments and therapies to slow or halt the progression of the disease.

Diabetic neuropathies refer to a group of nerve disorders that are caused by diabetes. High blood sugar levels can injure nerves throughout the body, but diabetic neuropathies most commonly affect the nerves in the legs and feet.

There are four main types of diabetic neuropathies:

1. Peripheral neuropathy: This is the most common type of diabetic neuropathy. It affects the nerves in the legs and feet, causing symptoms such as numbness, tingling, burning, or shooting pain.
2. Autonomic neuropathy: This type of neuropathy affects the autonomic nerves, which control involuntary functions such as heart rate, blood pressure, digestion, and bladder function. Symptoms may include dizziness, fainting, digestive problems, sexual dysfunction, and difficulty regulating body temperature.
3. Proximal neuropathy: Also known as diabetic amyotrophy, this type of neuropathy affects the nerves in the hips, thighs, or buttocks, causing weakness, pain, and difficulty walking.
4. Focal neuropathy: This type of neuropathy affects a single nerve or group of nerves, causing symptoms such as weakness, numbness, or pain in the affected area. Focal neuropathies can occur anywhere in the body, but they are most common in the head, torso, and legs.

The risk of developing diabetic neuropathies increases with the duration of diabetes and poor blood sugar control. Other factors that may contribute to the development of diabetic neuropathies include genetics, age, smoking, and alcohol consumption.

Neural conduction is the process by which electrical signals, known as action potentials, are transmitted along the axon of a neuron (nerve cell) to transmit information between different parts of the nervous system. This electrical impulse is generated by the movement of ions across the neuronal membrane, and it propagates down the length of the axon until it reaches the synapse, where it can then stimulate the release of neurotransmitters to communicate with other neurons or target cells. The speed of neural conduction can vary depending on factors such as the diameter of the axon, the presence of myelin sheaths (which act as insulation and allow for faster conduction), and the temperature of the environment.

Electrodiagnosis, also known as electromyography (EMG), is a medical diagnostic procedure that evaluates the health and function of muscles and nerves. It measures the electrical activity of skeletal muscles at rest and during contraction, as well as the conduction of electrical signals along nerves.

The test involves inserting a thin needle electrode into the muscle to record its electrical activity. The physician will ask the patient to contract and relax the muscle while the electrical activity is recorded. The resulting data can help diagnose various neuromuscular disorders, such as nerve damage or muscle diseases, by identifying abnormalities in the electrical signals.

Electrodiagnosis can be used to diagnose conditions such as carpal tunnel syndrome, peripheral neuropathy, muscular dystrophy, and amyotrophic lateral sclerosis (ALS), among others. It is a valuable tool in the diagnosis and management of neuromuscular disorders, helping physicians to develop appropriate treatment plans for their patients.

Polyradiculoneuropathy is a medical term that refers to a condition affecting multiple nerve roots and peripheral nerves. It's a type of neuropathy, which is damage or disease affecting the peripheral nerves, and it involves damage to the nerve roots as they exit the spinal cord.

The term "poly" means many, "radiculo" refers to the nerve root, and "neuropathy" indicates a disorder of the nerves. Therefore, polyradiculoneuropathy implies that multiple nerve roots and peripheral nerves are affected.

This condition can result from various causes, such as infections (like Guillain-Barre syndrome), autoimmune disorders (such as lupus or rheumatoid arthritis), diabetes, cancer, or exposure to toxins. Symptoms may include weakness, numbness, tingling, or pain in the limbs, which can progress and become severe over time. Proper diagnosis and management are crucial for improving outcomes and preventing further nerve damage.

Demyelinating diseases are a group of disorders that are characterized by damage to the myelin sheath, which is the protective covering surrounding nerve fibers in the brain, optic nerves, and spinal cord. Myelin is essential for the rapid transmission of nerve impulses, and its damage results in disrupted communication between the brain and other parts of the body.

The most common demyelinating disease is multiple sclerosis (MS), where the immune system mistakenly attacks the myelin sheath. Other demyelinating diseases include:

1. Acute Disseminated Encephalomyelitis (ADEM): An autoimmune disorder that typically follows a viral infection or vaccination, causing widespread inflammation and demyelination in the brain and spinal cord.
2. Neuromyelitis Optica (NMO) or Devic's Disease: A rare autoimmune disorder that primarily affects the optic nerves and spinal cord, leading to severe vision loss and motor disability.
3. Transverse Myelitis: Inflammation of the spinal cord causing damage to both sides of one level (segment) of the spinal cord, resulting in various neurological symptoms such as muscle weakness, numbness, or pain, depending on which part of the spinal cord is affected.
4. Guillain-Barré Syndrome: An autoimmune disorder that causes rapid-onset muscle weakness, often beginning in the legs and spreading to the upper body, including the face and breathing muscles. It occurs when the immune system attacks the peripheral nerves' myelin sheath.
5. Central Pontine Myelinolysis (CPM): A rare neurological disorder caused by rapid shifts in sodium levels in the blood, leading to damage to the myelin sheath in a specific area of the brainstem called the pons.

These diseases can result in various symptoms, such as muscle weakness, numbness, vision loss, difficulty with balance and coordination, and cognitive impairment, depending on the location and extent of the demyelination. Treatment typically focuses on managing symptoms, modifying the immune system's response, and promoting nerve regeneration and remyelination when possible.

Gangliosides are a type of complex lipid molecule known as sialic acid-containing glycosphingolipids. They are predominantly found in the outer leaflet of the cell membrane, particularly in the nervous system. Gangliosides play crucial roles in various biological processes, including cell recognition, signal transduction, and cell adhesion. They are especially abundant in the ganglia (nerve cell clusters) of the peripheral and central nervous systems, hence their name.

Gangliosides consist of a hydrophobic ceramide portion and a hydrophilic oligosaccharide chain that contains one or more sialic acid residues. The composition and structure of these oligosaccharide chains can vary significantly among different gangliosides, leading to the classification of various subtypes, such as GM1, GD1a, GD1b, GT1b, and GQ1b.

Abnormalities in ganglioside metabolism or expression have been implicated in several neurological disorders, including Parkinson's disease, Alzheimer's disease, and various lysosomal storage diseases like Tay-Sachs and Gaucher's diseases. Additionally, certain bacterial toxins, such as botulinum neurotoxin and tetanus toxin, target gangliosides to gain entry into neuronal cells, causing their toxic effects.

I must clarify that the term "pedigree" is not typically used in medical definitions. Instead, it is often employed in genetics and breeding, where it refers to the recorded ancestry of an individual or a family, tracing the inheritance of specific traits or diseases. In human genetics, a pedigree can help illustrate the pattern of genetic inheritance in families over multiple generations. However, it is not a medical term with a specific clinical definition.

Phosphoric diester hydrolases are a class of enzymes that catalyze the hydrolysis of phosphoric diester bonds. These enzymes are also known as phosphatases or nucleotidases. They play important roles in various biological processes, such as signal transduction, metabolism, and regulation of cellular activities.

Phosphoric diester hydrolases can be further classified into several subclasses based on their substrate specificity and catalytic mechanism. For example, alkaline phosphatases (ALPs) are a group of phosphoric diester hydrolases that preferentially hydrolyze phosphomonoester bonds in a variety of organic molecules, releasing phosphate ions and alcohols. On the other hand, nucleotidases are a subclass of phosphoric diester hydrolases that specifically hydrolyze the phosphodiester bonds in nucleotides, releasing nucleosides and phosphate ions.

Overall, phosphoric diester hydrolases are essential for maintaining the balance of various cellular processes by regulating the levels of phosphorylated molecules and nucleotides.

Nerve degeneration, also known as neurodegeneration, is the progressive loss of structure and function of neurons, which can lead to cognitive decline, motor impairment, and various other symptoms. This process occurs due to a variety of factors, including genetics, environmental influences, and aging. It is a key feature in several neurological disorders such as Alzheimer's disease, Parkinson's disease, Huntington's disease, and multiple sclerosis. The degeneration can affect any part of the nervous system, leading to different symptoms depending on the location and extent of the damage.

Electromyography (EMG) is a medical diagnostic procedure that measures the electrical activity of skeletal muscles during contraction and at rest. It involves inserting a thin needle electrode into the muscle to record the electrical signals generated by the muscle fibers. These signals are then displayed on an oscilloscope and may be heard through a speaker.

EMG can help diagnose various neuromuscular disorders, such as muscle weakness, numbness, or pain, and can distinguish between muscle and nerve disorders. It is often used in conjunction with other diagnostic tests, such as nerve conduction studies, to provide a comprehensive evaluation of the nervous system.

EMG is typically performed by a neurologist or a physiatrist, and the procedure may cause some discomfort or pain, although this is usually minimal. The results of an EMG can help guide treatment decisions and monitor the progression of neuromuscular conditions over time.

... in such cases it has been called Giant axonal neuropathy with curly hair. Giant axonal neuropathy results from mutations in the ... Library of Medicine Giant axonal neuropathy at NLM Genetics Home Reference GeneReview/NIH/UW entry on Giant Axonal Neuropathy ( ... Giant axonal neuropathy is a rare, autosomal recessive neurological disorder that causes disorganization of neurofilaments. ... Abnormally kinky hair is characteristic of giant axonal neuropathy, appearing in almost all cases. As the disorder progresses, ...
... ... the Company will discontinue the development of its TSHA-120 program in evaluation for the treatment of giant axonal neuropathy ...
Perioperative Management of a Patient With Giant Axonal Neuropathy ... Perioperative Management of a Patient With Giant Axonal Neuropathy. Hiromi Kakoa, b, d, Arlyne Thunga, b, Allan Beebec, Jan ... Yang Y, Allen E, Ding J, Wang W. Giant axonal neuropathy. Cell Mol Life Sci. 2007;64(5):601-609.. doi pubmed ... Gordon N. Giant axonal neuropathy. Dev Med Child Neurol. 2004;46(10):717-719.. doi pubmed ...
The inherited Charcot-Marie-Tooth peripheral neuropathies (CMT) were first described independently by Charcot and Marie in ... Axonal neuropathy due to myelin protein zero mutation misdiagnosed as amyloid neuropathy. Muscle Nerve. 2008 Jul. 38(1):921-3. ... This suggests that, in most cases, axonal damage is the root cause of the neuropathy, not demyelination. [6] However, the gene ... Mechanisms of disease: a molecular genetic update on hereditary axonal neuropathies. Nat Clin Pract Neurol. 2006. 2:45-53. [ ...
Giant axonal disease, see Giant axonal neuropathy. *Giant axonal neuropathy. *Giant cell chondrodysplasia, see Atelosteogenesis ... Giant congenital pigmented nevus, see Giant congenital melanocytic nevus. *Giant parietal foramina, see Enlarged parietal ... Gamstorp-Wohlfart syndrome, see Autosomal recessive axonal neuropathy with neuromyotonia. *GAMT deficiency, see ... Glomerulopathy with giant fibrillar deposits, see Fibronectin glomerulopathy. *Glossoptosis, micrognathia, and cleft palate, ...
The inherited Charcot-Marie-Tooth peripheral neuropathies (CMT) were first described independently by Charcot and Marie in ... Axonal neuropathy due to myelin protein zero mutation misdiagnosed as amyloid neuropathy. Muscle Nerve. 2008 Jul. 38(1):921-3. ... This suggests that, in most cases, axonal damage is the root cause of the neuropathy, not demyelination. [6] However, the gene ... Mechanisms of disease: a molecular genetic update on hereditary axonal neuropathies. Nat Clin Pract Neurol. 2006. 2:45-53. [ ...
Animals, Cytoskeletal Proteins, Female, Giant Axonal Neuropathy, Humans, Intermediate Filament Proteins, Intermediate Filaments ... p,Research on pathogenic mechanisms underlying giant axonal neuropathy (GAN), a disease caused by a deficiency of gigaxonin, ... A New Mouse Model of Giant Axonal Neuropathy with Overt Phenotypes and Neurodegeneration Driven by Neurofilament ... Giant axons (≥160 μm) enlarged by disorganized IFs, a hallmark of GAN disease, were also detected in dorsal and ventral roots ...
Giant axonal neuropathy (GAN) is definitely a progressive neurodegenerative disease caused. Giant axonal neuropathy (GAN) is ... 1 2 Patients with giant axonal neuropathy (GAN) provide a particularly striking example: peripheral nerve biopsies show ... usually a feature of several neurodegenerative disorders including amyotrophic lateral sclerosis Parkinsons disease and axonal ...
Giant Axonal Neuropathy: Everything You Need to Know. Medically reviewed by Mia Armstrong, MD ...
giant axonal neuropathy 1 Gilles de la Tourette syndrome + Gillespie syndrome Gingival Fibromatosis with Distinctive Facies ... Autosomal Recessive Peripheral Neuropathy with or without Impaired Intellectual Development autosomal recessive polycystic ...
She learned that his diagnosis was GAN, or giant axonal neuropathy.. The disease is an extremely rare neurodegenerative ...
Giant axonal neuropathy. *Glucose transporter type 1 deficiency. *Glutathione synthase deficiency. *Glycerol kinase deficiency ...
... giant axonal neuropathy, familial dysautonomia) and inflammatory or autoimmune peripheral neuropathies (e.g. myasthenia gravis ... and chemotherapy induced-peripheral neuropathies. Early pattern formation; neural polarity and migration; axonal guidance; ... Responses to spinal cord injury or peripheral nerve injury, including axonal regeneration; interventions to promote recovery ... Muscular dystrophies; spinal muscular atrophy and inherited peripheral neuropathies (e.g. Charcot-Marie-Tooth, ...
Raising global awareness of inherited neuropathies is a daily challenge we face head on at The Hereditary Neuropathy Foundation ... One of these rare genetic diseases is Giant Axonal Neuropathy: an autosomal recessive genetic disorder caused by mutations on ... At four years old, she was diagnosed with an extremely rare genetic defect called Giant Axonal Neuropathy (GAN). The disease ... community to receive a therapeutic gene to the spinal cord for an ultra rare inherited neuropathy is Giant Axonal Neuropathy ( ...
Post on October 09, 2018 from our Patient & Family, North America, GAN, Giant Axonal Neuropathy ... a geneticist suggested Jordan has a highly rare genetic illness called Giant Axonal Neuropathy (GAN). The incurable disease ...
Giant Axonal Neuropathy. Abnormal pituitary gland morphology. ORPHA:643. Magel2-Related Prader-Willi-Like Syndrome. ...
Giant Axonal Neuropathy. ... Primary peripheral axonal neuropathy (CMT2 or HMSN-II) with ... A Practical Approach to the Genetic Neuropathies, March 2015. The Inherited Neuropathies Consortium. The Inherited Neuropathies ... is primarily an axonal disorder, not a demyelinating disorder. CMT2 results in peripheral neuropathy through direct axonal ... CMT (Charcot-Marie-Tooth) disease is a heterogeneous group of inherited peripheral neuropathies in which the neuropathy is the ...
... and demyelinated axons with a similar appearance to the giant axonal swellings characteristic of systemic hexacarbon neuropathy ... The authors conclude that 25HD can induce the formation of giant axonal swellings through direct toxic action and that the ... V. axonal neurofilaments accumulate at sites of 2,5-hexanedione application: evidence for nerve fibre dysfunction in ... but animals exposed to 25HD in the drinking water and by direct nerve application had a higher incidence of axonal swellings. ...
Giant axonal neuropathy: acceleration of neurofilament transport in optic axons. Proceedings of the National Academy of ... Experimental diabetic neuropathy: similar changes of slow axonal transport and axonal size in different animal models. The ... 38 Slow Axonal Transport In Carbon Disulfide (Cs2) Giant Axonopathy Journal of Neuropathology and Experimental Neurology. 43: ... Changes in axon size and slow axonal transport are related in experimental diabetic neuropathy. Neurology. 38: 597-601. PMID ...
... she contributed to developing AAV-based gene therapies for Giant Axonal Neuropathy, Charcot-Marie-Tooth disease type 4J, and ...
... she contributed to developing AAV-based gene therapies for Giant Axonal Neuropathy, Charcot-Marie-Tooth disease type 4J, and ...
... following their youngest daughters diagnosis of Giant Axonal Neuropathy (GAN) in 2008. GAN is the most rare, and one of the ... The Hereditary Neuropathy Foundation (HNF) has committed to spend 30 days in September hosting local and national events, ... Make a donation to the Hereditary Neuropathy Foundation to help find treatments and cures for those living with Charcot-Marie- ... Copyright © 2023 Hereditary Neuropathy Foundation , 1641 3rd Avenue #28K New York, NY 10128 , Powered by COMMbits ...
... sometimes called classic giant axonal neuropathy) to milder pure early-onset peripheral motor and sensory neuropathies. The ... Giant axonal neuropathy 1. GAN-related neurodegeneration comprises a phenotypic continuum ranging from severe ( ... including a progressive sensorimotor axonal neuropathy and deafness due to auditory neuropathy. Additional more variable ... Motor axonal neuropathy. Progressive impairment of function of motor axons with muscle weakness, atrophy, and cramps. The ...
Astellas an option to license its gene therapy candidate TSHA-120 in the neurodegenerative disorder giant axonal neuropathy ( ...
Sonic Hedgehog repression underlies gigaxonin mutation-induced motor deficits in giant axonal neuropathy.. Arribat Y*, Mysiak ...
Taysha Gene Therapies Halts its TSHA-120 Program for Giant Axonal Neuropathy Treatment. Taysha is discontinuing the development ... Taysha Gene Therapies Halts its TSHA-120 Program for Giant Axonal Neuropathy Treatment. ...
GAN (Giant axonal neuropathy). Other. *desmoplakin: Striate palmoplantar keratoderma 2. *Carvajal syndrome ...
Giant Axonal Neuropathy Whats New Last Posted: Dec 18, 2020 * Current Clinical Applications of in vivo Gene Therapy with AAVs. ...

No FAQ available that match "giant axonal neuropathy"

No images available that match "giant axonal neuropathy"